Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Therapeutic Research Protocol Dose: 2 mg Tesamorelin + 300 mcg Ipamorelin Duration: 12 16 weeks Frequency: Daily, evening administration Cycle Interval: 6 8 weeks off before repeating Goal / Description: Higher-dose protocol for visceral fat reduction and IGF-1 elevation studies
Medical services are provided under the supervision of a licensed physician or authorized healthcare provider
Additionally, IGF-1 levels, the primary mediator of many GH effects, show dose-dependent increases in response to combined CJC-1295 and Ipamorelin treatment in rodent models
doi:10.1016/s2213-8587(18)30104-9
Neither compound has been robustly quantified in controlled human appetite studies
US$ 20.04
US$ 27.61
US$ 25.79
US$ 23.80
US$ 27.29
US$ 24.95
US$ 22.63
US$ 29.65
